*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Dyadic International, Inc. (Nasdaq: DYAI)
DYAI is our brand new Nasdaq high-growth alert.
This is a hidden gem opportunity that not many have seen and we are among the first to bring it to your attention.
Plus, the company sits at the intersection of some of the hottest themes today, pandemic preparedness, AI-enabled drug discovery, and animal-free protein manufacturing.
The chart setup is pointing to a potential breakout opportunity.
This means that momentum can build very quickly.
And it is still trading for under 1.00.
In addition, just this morning, the company announced breaking news.
DYAI is a NASDAQ listed “global biotechnology company”.
DYAI “aims to develop and commercialize scalable, non-animal protein production platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets”.
These “high-value proteins are designed to enable customers to develop more efficient, scalable, and sustainable products”.
The company’s “proprietary Dapibus™ and C1 expression systems support rapid, cost-effective, and flexible manufacturing.”
The recent Ebola-related preparedness activity has brought renewed attention to one of the most important challenges in global health: the ability to rapidly manufacture vaccines, monoclonal antibodies and other biologics at sufficient scale and affordable cost.
DYAI “believes its C1 platform is well positioned to help address this challenge through rapid strain development, high expression levels, flexible microbial manufacturing and reduced production timelines.”
The company’s “C1 platform has demonstrated the ability to progress from receipt of a codon-optimized viral gene sequence to purified recombinant antigen or monoclonal antibody in approximately 15 days.”
DYAI “believes this speed may be particularly important during infectious disease outbreaks, where response time, manufacturing capacity and equitable access can directly affect preparedness outcomes.”
According to Mark A. Emalfarb, Chief Executive Officer of Dyadic Applied BioSolutions:
"Scientific discovery alone is not enough.”
“Vaccines and antibody therapies that cannot be manufactured quickly, affordably and at sufficient scale are unable to reach the people who need them most.”
“A vaccine or antibody that is unavailable or unaffordable is 100% ineffective. Manufacturing matters."
What makes DYAI exciting is that they have “two complementary protein production platforms designed to serve distinct but significant markets.”
The “C1 platform is focused on life sciences and biopharmaceutical applications, including pandemic preparedness, vaccine antigens, monoclonal antibodies, other biologics, diagnostics and cell culture inputs.”
The “Dapibus™ platform is designed to support the commercialization of recombinant proteins and enzymes across food, nutrition, wellness and bioindustrial markets, including animal-free ingredients, precision fermentation, specialty enzymes and industrial biotechnology applications.”
Together, these platforms are “targeting current addressable market opportunities that Dyadic estimates exceed $25 billion across life sciences, food/nutrition, wellness and bioindustrial applications.”
Furthermore, as demand continues to grow for biologics, animal-free proteins, cell culture inputs and industrial enzymes, DYAI’s “platforms are increasingly well positioned to support both global health initiatives and commercial market opportunities."
DYAI “believes this multi-market approach provides several potential pathways for long-term value creation while reducing dependence on any single clinical program, outbreak event or commercial product.”
The company has announced multiple accomplishments recently.
On May 13, 2026, the company announced:
“Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress”
Recent Company Developments and Updates:
Life Sciences
“Recombinant Serum Albumin (AlbuFree™ DX): In February 2026, Proliant Health and Biologicals announced the commercial launch of AlbuFree™ DX recombinant human albumin, produced using Dyadic's production platform. Dyadic is entitled to a share of profits from commercial sales.
OEM Distribution Agreement with IBT Bioservices: In March 2026, Dyadic entered into an OEM distribution agreement with IBT Bioservices to support commercialization of multiple recombinant proteins and enzymes through IBT's global distribution channels. Initial product quantities, including DNase I and transferrin, have been completed and shipped to support channel commercialization activities.
DNase-1 (RNase-free): Dyadic completed production validation of recombinant DNase I and, together with Fermbox Bio, commercially launched DNase I (RNase-free) as the first product under their expanded collaboration.
Recombinant Transferrin and Growth Factors: Dyadic continues advancing its animal-free transferrin and fibroblast growth factor (FGF) products for use in cell culture media, diagnostics, and research, with expanded customer interest and sampling activity for recombinant bovine transferrin within the cultivated meat industry.
Reagent Proteins and Nucleic Acid Enzymes: Dyadic continues advancing a portfolio of enzymes for DNA and RNA manipulation, including RNase inhibitors and T7 RNA polymerase.
Food and Nutrition
Alpha-Lactalbumin: In December 2025, Dyadic signed a development and commercialization agreement with BRIG Bio to create recombinant bovine alpha-lactalbumin for global nutrition markets. Product development activities have been initiated, including initial product quality and application testing, with customer sampling activities expected to begin in mid-2026.
Human Lactoferrin: Dyadic has established a stable cell line for recombinant human lactoferrin production and is continuing optimization and characterization efforts supporting future nutrition applications.
Non-Animal Dairy Enzymes: Dyadic's partner Inzymes has commercialized recombinant non-animal bovine chymosin following achievement of development milestones under its agreement with Dyadic.
Food and Nutrition Pipeline Expansion: Dyadic anticipates broadening both partner-led and internal development programs focused on non-animal dairy proteins, selected food and nutrition enzymes, and related baking and brewing enzyme applications.
Bio-Industrial Products
Expanded Fermbox Bio Collaboration: Dyadic expanded its collaboration with Fermbox Bio to support the development and manufacturing of animal-free recombinant proteins and enzymes across life sciences, food and nutrition, and bio-industrial markets.
EN3ZYME™ Platform: Fermbox Bio previously launched EN3ZYME™, an enzyme cocktail produced using the Dapibus™ platform that converts agricultural residues into fermentable cellulosic sugars and fulfilled its first large scale order in 2025, with sampling activity now extending into the Asia Pacific region.
Biopharmaceutical Programs
Gates Foundation-supported RSV and malaria monoclonal antibody programs and the CEPI/Fondazione Biotecnopolo di Siena ("FBS") H5 avian influenza antigen program continued to advance toward preclinical evaluation, with C1-produced antigens and antibodies expressed at high yields while demonstrating binding and neutralization profiles virtually identical to CHO-derived clinical reference materials.
Collaborative development activities with Fondazione Biotecnopolo di Siena ("FBS") continue to demonstrate rapid antigen development timelines and the ability to progress from receipt of a codon-optimized plasmid to purified recombinant antigen candidates within weeks, while multiple preclinical animal studies evaluating C1-produced H5 (avian influenza), RSV and malaria antigens were initiated, with initial data readouts demonstrating high levels of neutralizing antibodies.
Corporate Development
Expanding Commercial Efforts in Asia and Europe: Dyadic expanded its engagement with Intralink to include Europe in addition to Japan and South Korea, supporting broader commercial development activities and market entry initiatives for Dyadic's animal-free proteins.
Commercial Scale-Up Activities: Together with Fermbox Bio and other manufacturing partners, Dyadic continues scaling production capabilities for multiple recombinant proteins and enzymes, including transferrin and additional commercial-stage products, to support broader market launch activities and channel expansion.
Expanding Commercial Partnerships and Distribution Channels: Dyadic continues prioritizing relationships with manufacturing, supply chain, and distribution partners to support commercialization and broaden market access for its growing portfolio of recombinant proteins and enzymes.
Commercialization and Channel Expansion Strategy: Dyadic is focused on increasing product availability through both direct and partner-led commercialization efforts, including OEM distribution, regional business development partnerships, and strategic manufacturing collaborations designed to support long-term recurring product revenue opportunities.”
On May 28, 2026, the company announced:
“Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development”
DYAI announced that “Dyadic Applied BioSolutions and researchers at Scripps Research are collaborating to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, a hantavirus strain associated with Hantavirus Pulmonary Syndrome (HPS), a severe and potentially fatal respiratory disease in humans.”
The collaboration “builds upon Dyadic's prior Andes virus monoclonal antibody work and combines the complementary expertise of Dyadic and Scripps Research to further assess the potential of Dyadic's proprietary C1 platform for rapid development timelines, high-productivity microbial fermentation, large-scale manufacturing, and biologic production intended to support future infectious disease preparedness.”
Mark Emalfarb, Dyadic's Chief Executive Officer, commented:
"COVID-19 demonstrated that manufacturing scalability and deployment speed remain critical challenges during global outbreaks," said Mark Emalfarb, Dyadic's Chief Executive Officer. "Our collaboration with Scripps builds upon prior hantavirus-related work and reflects our broader strategy of partnering with leading research institutions and global health organizations to evaluate how we anticipate the C1 platform will contribute to future pandemic preparedness initiatives."
Jiang Zhu, Professor at Scripps Research, added:
"One of the key lessons from recent global outbreaks is that scientific innovation alone is not sufficient — manufacturing flexibility, scale and speed are also critical," said Jiang Zhu, Professor at Scripps Research. "Collaborations that bring together advanced antibody and antigen research with rapid biologic production technologies may help strengthen preparedness for future infectious disease threats."
Dr. Zhu continued, "My laboratory at Scripps Research has developed proprietary structure-based protein designs optimized for conformational integrity, trimer closure, and antigen quality. In parallel, innovative expression technologies such as Dyadic's C1 platform may offer opportunities to further evaluate faster, more scalable and potentially lower-cost approaches for the development and manufacture of complex biologics targeting emerging infectious diseases."
On June 15, 2026, the company announced:
“Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption”
DYAI “highlighted increasing interest in its proprietary C1 protein production platform as global infectious disease preparedness efforts intensify in response to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and as the Company continues to advance commercial adoption across multiple high-growth markets.
Importantly, DYAI’s “Dyadic's C1 platform has demonstrated the ability to progress from receipt of a codon-optimized viral gene sequence to purified recombinant antigen or monoclonal antibody in approximately 15 days.”
Recent commercial and development milestones include:
“Launch of recombinant human albumin through Proliant Health & Biologicals
Commercialization of recombinant DNase I through Fermbox Bio
Global distribution activities through IBT Bioservices
Commercialization of recombinant bovine chymosin through Inzymes
Advancement of recombinant transferrin and growth factor products targeting cell culture media, cultivated meat, biomanufacturing and other high-growth life sciences applications”
Last week, the company announced:
“Dyadic Expands IP Protection and Business Development Activities in Japan”
“Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions”
“Japan is a strategic market for Dyadic, recognized for its leadership in regenerative medicine, biologics manufacturing, precision fermentation, advanced bioprocessing, biopharmaceuticals, cosmetics, food and nutrition technologies, and life sciences innovation.
The Company believes its enhanced intellectual property protection, Intralink's local business development support, and planned in-country engagements position Dyadic to capitalize on growing demand for scalable recombinant protein solutions.”
Here are some of the company’s comments from this press release:
"This patent represents an important milestone in our strategy to expand Dyadic's intellectual property position and commercial opportunities in one of the world's most advanced biotechnology markets," said Joe Hazelton, Dyadic's President and Chief Operating Officer.
Plus:
"As we continue transforming Dyadic into a recombinant protein solutions company, expanding our presence in key global biotechnology markets is an important component of our long-term growth strategy," added Mr. Hazelton. "Our collaboration with Intralink has accelerated business development efforts in Japan and helped establish meaningful discussions with organizations seeking flexible, scalable, and cost-effective protein production solutions."
In addition, just this morning, the company announced breaking news:
“Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential”
“C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding”
We believe DYAI could be positioned for big upside potential.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated nine thousand dollars by bank wire transfer on 7/1/26 for the distribution of this advertisement about DYAI dated 7/7/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.